HRP20191982T1 - Kombinacijsko liječenje raka - Google Patents
Kombinacijsko liječenje raka Download PDFInfo
- Publication number
- HRP20191982T1 HRP20191982T1 HRP20191982TT HRP20191982T HRP20191982T1 HR P20191982 T1 HRP20191982 T1 HR P20191982T1 HR P20191982T T HRP20191982T T HR P20191982TT HR P20191982 T HRP20191982 T HR P20191982T HR P20191982 T1 HRP20191982 T1 HR P20191982T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- prostate cancer
- azd5363
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 13
- 206010060862 Prostate cancer Diseases 0.000 claims 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 11
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims 10
- 239000003085 diluting agent Substances 0.000 claims 6
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 5
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 4
- 229960000997 bicalutamide Drugs 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 229960004671 enzalutamide Drugs 0.000 claims 4
- 102000001307 androgen receptors Human genes 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Kombinacija koja sadrži:
(S)-4-amino-N-(1-(4-klorofenil)-3-hidroksipropil)-1-(7H-pirolo[2,3-d]pirimidin-4-il)piperidin-4-karboksamid (AZD5363), ili njegovu farmaceutski prihvatljivu sol;
s modulatorom signalizacije androgenih receptora odabranim od:
4-{3-[4-cijano-3-(trifluorometil)-fenil]-5,5-dimetil-4-okso-2-tioksoimidazolidin-1-il}-2-fluoro-N-metilbenzamida (MDV-3100) ; i
N-[4-cijano-3-(trifluorometil)-fenil]-3-[(4-fluorofenil)-sulfonil]-2-hidroksi-2-metilpropanamida (bikalutamid);
ili njihovu farmaceutski prihvatljivu sol.
2. Kombinacija prema patentnom zahtjevu 1, naznačena time što sadrži AZD5363, ili njegovu farmaceutski prihvatljivu sol; s modulatorom signalizacije androgenih receptora koji je MDV-3100.
3. Kombinacija prema patentnom zahtjevu 1, naznačena time što sadrži AZD5363, ili njegovu farmaceutski prihvatljivu sol; s modulatorom signalizacije androgenih receptora koji je bikalutamid; ili njegova farmaceutski prihvatljiva sol.
4. Kombinacija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je za uporabu kao lijek za liječenje raka prostate.
5. Kombinacija za uporabu kako je zatraženo u zahtjevu 4, naznačena time što je rak prostate, rak prostate otporan na kastraciju.
6. Komplet naznačen time što sadrži:
(a) AZD5363, ili farmaceutski prihvatljivu sol, u prvom obliku jedinične doze;
(b) MDV-3100 u drugom obliku jedinične doze;
(c) sredstva za pohranu koja sadržavaju navedeni prvi i drugi oblik doziranja;
i proizvoljno, upute za upotrebu.
7. Komplet naznačen time što sadrži:
(a) AZD5363, ili farmaceutski prihvatljivu sol, u prvom obliku jedinične doze;
(b) bikalutamid; ili njegova farmaceutski prihvatljiva sol, u drugom obliku jedinične doze;
(c) sredstva za pohranu koja sadržavaju navedeni prvi i drugi oblik doziranja;
i proizvoljno, upute za upotrebu.
8. Komplet prema patentnom zahtjevu 6 ili 7, naznačen time što je komplet za uporabu za liječenje raka prostate.
9. Komplet prema patentnom zahtjevu 8, naznačen time što je komplet za uporabu za liječenje raka prostate otpornog na kastraciju.
10. AZD5363, ili njegova farmaceutski prihvatljiva sol, proizvoljno zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem, za uporabu za liječenje raka prostate, naznačen time što navedeno liječenje uključuje istovremeno, odvojeno ili uzastopno davanje MDV-3100, proizvoljno zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
11. AZD5363, ili njegova farmaceutski prihvatljiva sol, proizvoljno zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem, za uporabu za liječenje raka prostate, naznačen time što navedeno liječenje uključuje istovremeno, odvojeno ili uzastopno davanje bikalutamida, ili njegove farmaceutski prihvatljive soli, proizvoljno zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
12. AZD5363, ili njegova farmaceutski prihvatljiva sol, proizvoljno zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem, za uporabu kako je zatraženo u zahtjevu 10 ili 11, naznačen time što je rak prostate rak prostate otporan na kastraciju
13. AZD5363, ili njegova farmaceutski prihvatljiva sol, proizvoljno zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem, za uporabu kako je zatraženo u zahtjevu 10 ili 11, naznačen time što je rak prostate metastatski rak prostate otporan na kastraciju.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564975P | 2011-11-30 | 2011-11-30 | |
| PCT/GB2012/052969 WO2013079964A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
| EP12795842.9A EP2785349B2 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20191982T1 true HRP20191982T1 (hr) | 2020-02-07 |
| HRP20191982T4 HRP20191982T4 (hr) | 2023-01-06 |
Family
ID=47295082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191982TT HRP20191982T4 (hr) | 2011-11-30 | 2012-11-30 | Kombinacijsko liječenje raka |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20140329786A1 (hr) |
| EP (1) | EP2785349B2 (hr) |
| JP (1) | JP6309454B2 (hr) |
| KR (1) | KR102035361B1 (hr) |
| CN (1) | CN103945849B (hr) |
| AU (1) | AU2012321110B2 (hr) |
| CA (1) | CA2856646C (hr) |
| CY (1) | CY1122624T1 (hr) |
| DK (1) | DK2785349T4 (hr) |
| ES (1) | ES2762250T5 (hr) |
| FI (1) | FI2785349T4 (hr) |
| HK (1) | HK1202253A1 (hr) |
| HR (1) | HRP20191982T4 (hr) |
| HU (1) | HUE046667T2 (hr) |
| IL (1) | IL232530B (hr) |
| LT (1) | LT2785349T (hr) |
| MX (1) | MX367640B (hr) |
| MY (1) | MY175800A (hr) |
| PL (1) | PL2785349T5 (hr) |
| PT (1) | PT2785349T (hr) |
| RS (1) | RS59493B2 (hr) |
| RU (1) | RU2640485C2 (hr) |
| SG (1) | SG11201401471PA (hr) |
| SI (1) | SI2785349T2 (hr) |
| WO (1) | WO2013079964A1 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2010040020A1 (en) | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| MX355915B (es) | 2010-02-16 | 2018-05-04 | Aragon Pharmaceuticals Inc | Moduladores del receptor de androgenos y usos de los mismos. |
| JP6100700B2 (ja) | 2011-01-11 | 2017-03-22 | ノバルティス アーゲー | 組合せ |
| AU2012358219A1 (en) * | 2011-12-22 | 2014-07-10 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using P13K/mTOR inhibitors |
| AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| EA202190820A1 (ru) * | 2012-09-26 | 2021-10-29 | Арагон Фармасьютикалз, Инк. | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| CN109674801A (zh) * | 2013-10-01 | 2019-04-26 | 诺华股份有限公司 | 组合 |
| AU2014330780B2 (en) * | 2013-10-01 | 2017-05-25 | Novartis Ag | Enzalutamide in combination with Afuresertib for the treatment of cancer |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| ES2900149T3 (es) | 2016-07-21 | 2022-03-16 | Hadasit Med Res Service | Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma |
| JP7048106B2 (ja) * | 2016-12-16 | 2022-04-05 | カンプ・バイオファーマスーティカルズ、リミテッド | 組み合わせ、その用途及び処置方法 |
| CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| CN111107852A (zh) * | 2017-09-22 | 2020-05-05 | 分散技术有限责任公司 | 阿比特龙-环状寡聚体药物制剂及其形成和施用方法 |
| WO2019078920A1 (en) | 2017-10-16 | 2019-04-25 | Aragon Pharmaceuticals, Inc. | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER |
| CN108486041A (zh) * | 2018-03-28 | 2018-09-04 | 华南农业大学 | PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637271A (hr) | 1963-04-04 | 1900-01-01 | ||
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| DK0633893T3 (da) | 1992-03-31 | 2000-04-17 | Btg Int Ltd | 17-Substituerede steroider, der er nyttige ved cancerbehandling |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| AU715202B2 (en) | 1996-04-03 | 2000-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| BRPI9810945B8 (pt) | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
| HUP0002956A3 (en) | 1997-08-05 | 2002-01-28 | Pfizer Prod Inc | Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| PL345906A1 (en) | 1998-06-04 | 2002-01-14 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| YU83302A (sh) | 2000-06-26 | 2005-09-19 | Pfizer Products Inc. | Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi |
| BR0113585A (pt) | 2000-08-31 | 2003-07-29 | Hoffmann La Roche | Derivados quinazolina como antagonistas adrenérgicos alfa-1 |
| NZ525885A (en) | 2000-12-01 | 2005-01-28 | Osi Pharm Inc | Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020182204A1 (en) | 2001-03-23 | 2002-12-05 | Marie-Christine Bissery | Combination of a taxane and a cyclin-dependent kinase |
| IL162884A0 (en) | 2002-01-07 | 2005-11-20 | Eisai Co Ltd | Deazapurines and uses thereof |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| MEP16308A (hr) | 2002-05-17 | 2010-06-10 | Aventis Pharma Sa | Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika |
| TW200410688A (en) | 2002-06-26 | 2004-07-01 | Ono Pharmaceutical Co | Therapeutics for diseases from vasoconstriction or vasodilatation |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| JP2006503826A (ja) | 2002-09-06 | 2006-02-02 | スミスクライン・ビーチャム・コーポレイション | ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物 |
| US20060159617A1 (en) | 2002-11-08 | 2006-07-20 | Ashfaq Mahmood | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| EP1568699A4 (en) | 2002-12-04 | 2007-08-15 | Eisai R&D Man Co Ltd | 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING |
| US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
| EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| WO2004094426A1 (en) | 2003-04-21 | 2004-11-04 | Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky | (purin-6-yl) amino acid and production method thereof |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
| EP1698375B1 (en) | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CA2590961C (en) | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| WO2006090129A2 (en) * | 2005-02-23 | 2006-08-31 | Astrazeneca Ab | Bicalutamide for delivering increasing steady state plasma levels |
| RS52274B2 (sr) | 2005-05-13 | 2018-05-31 | Univ California | Jedinjenje diarilhidantoina |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| ES2719093T3 (es) | 2005-08-31 | 2019-07-08 | Abraxis Bioscience Llc | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación |
| TW200738709A (en) | 2006-01-19 | 2007-10-16 | Osi Pharm Inc | Fused heterobicyclic kinase inhibitors |
| WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2007125310A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| WO2007125325A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| MX2009006700A (es) | 2006-12-21 | 2009-06-30 | Vertex Pharma | Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas. |
| NZ585261A (en) * | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
| US20110312916A1 (en) * | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| KR20110113755A (ko) * | 2009-02-10 | 2011-10-18 | 아스트라제네카 아베 | 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도 |
| WO2011029782A1 (en) * | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| BR112012027745A2 (pt) * | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
-
2012
- 2012-11-30 PT PT127958429T patent/PT2785349T/pt unknown
- 2012-11-30 MX MX2014006547A patent/MX367640B/es active IP Right Grant
- 2012-11-30 LT LT12795842T patent/LT2785349T/lt unknown
- 2012-11-30 HR HRP20191982TT patent/HRP20191982T4/hr unknown
- 2012-11-30 WO PCT/GB2012/052969 patent/WO2013079964A1/en active Application Filing
- 2012-11-30 CN CN201280059109.1A patent/CN103945849B/zh active Active
- 2012-11-30 HU HUE12795842A patent/HUE046667T2/hu unknown
- 2012-11-30 MY MYPI2014701394A patent/MY175800A/en unknown
- 2012-11-30 US US14/361,718 patent/US20140329786A1/en not_active Abandoned
- 2012-11-30 AU AU2012321110A patent/AU2012321110B2/en active Active
- 2012-11-30 DK DK12795842.9T patent/DK2785349T4/da active
- 2012-11-30 RS RS20191392A patent/RS59493B2/sr unknown
- 2012-11-30 FI FIEP12795842.9T patent/FI2785349T4/fi active
- 2012-11-30 CA CA2856646A patent/CA2856646C/en active Active
- 2012-11-30 PL PL12795842.9T patent/PL2785349T5/pl unknown
- 2012-11-30 JP JP2014543977A patent/JP6309454B2/ja active Active
- 2012-11-30 SG SG11201401471PA patent/SG11201401471PA/en unknown
- 2012-11-30 EP EP12795842.9A patent/EP2785349B2/en active Active
- 2012-11-30 RU RU2014119713A patent/RU2640485C2/ru active
- 2012-11-30 KR KR1020147016680A patent/KR102035361B1/ko active IP Right Grant
- 2012-11-30 SI SI201231690T patent/SI2785349T2/sl unknown
- 2012-11-30 ES ES12795842T patent/ES2762250T5/es active Active
-
2014
- 2014-05-08 IL IL232530A patent/IL232530B/en active IP Right Grant
-
2015
- 2015-03-18 HK HK15102783.0A patent/HK1202253A1/xx unknown
-
2016
- 2016-02-08 US US15/018,157 patent/US9737540B2/en active Active
-
2019
- 2019-12-17 CY CY20191101323T patent/CY1122624T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191982T1 (hr) | Kombinacijsko liječenje raka | |
| AR097680A1 (es) | Sistema de distribución de fluidos con cámaras y formulaciones múltiples | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| CL2017001249A1 (es) | Forma cristalina de sulfato de hidrógeno (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidinaa-1-il)-pirazolo[1,5-a] pirimidinaa-3-il)-3-hidroxipirrolidinaa-1-carboxamida. | |
| JP2015500225A5 (hr) | ||
| ZA201500728B (en) | Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone | |
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| MX2020005645A (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido. | |
| WO2012065022A3 (en) | Spiro-oxindole mdm2 antagonists | |
| PH12016500420A1 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| JP2015530399A5 (hr) | ||
| EA201400165A1 (ru) | Частицы на основе полиакрилата, которые содержат активное соединение | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| EA201400210A1 (ru) | Применение и агрохимическая композиция дибутиламидов карбоновой кислоты | |
| WO2012145575A3 (en) | Therapy for leukemia | |
| IL227611A0 (en) | Treatment dosage, medication distribution package, and their uses for the treatment of depressive disorders | |
| HRP20191927T1 (hr) | Terapijsko liječenje | |
| CL2016000788A1 (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016) | |
| MY175052A (en) | Crystalline forms of (s) -4-amino-n- (1- (4 - chlorophenyl) - 3 - hydroxypropyl) -1- (7h - pyrrolo [2, 3-d] pyrimidi n-4-yl) piperidine-4-carboxamide | |
| IT1400708B1 (it) | Dispositivo per la ricostituzione dosata e la somministrazione di soluzioni liquide contenenti sostanze attive disponibili in forma separata, in particolare in polvere o gel. | |
| UA101083C2 (ru) | Футляр-смеситель для косметических веществ | |
| WO2013112873A3 (en) | Compositions and methods for improving lactation | |
| Фендриков | Teory of the beginning of universe | |
| Kurin | How I Initiated the Bankruptcy Proceeding |